Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.67 |
| ▸ | CA1 | P00915 | 16/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 12/20 | 0.61 |
| ▸ | CA9 | Q16790 | 12/20 | 0.61 |
| ▸ | CA5A | P35218 | 10/20 | 0.61 |
| ▸ | CA7 | P43166 | 10/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 10/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 9/20 | 0.61 |
| ▸ | CA6 | P23280 | 7/20 | 0.61 |
| ▸ | CA4 | P22748 | 6/20 | 0.61 |
| ▸ | CA3 | P07451 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.54 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzenesulfonamide SCHEMBL28510376 | 0.88 | AKR1B1 (0.65) | CA2CA1CA12CA9CA5A | |
| SCHEMBL7284782 | 0.83 | CA2 (0.67) | CA2CA1KDM4ESMN1; SMN2CA12 | |
| SCHEMBL2674394 | 0.83 | CA2 (0.62) | CA2CA1KDM4ESMN1; SMN2CA12 | |
| SCHEMBL11516453 | 0.82 | CA2 (0.59) | CA2CA1KDM4ESMN1; SMN2CA12 | |
| SCHEMBL2397879 | 0.82 | SMN1; SMN2 (0.65) | CA2CA1KDM4ESMN1; SMN2CA12 | |
| SCHEMBL396733 | 0.81 | CA2 (0.54) | CA2CA1KDM4ESMN1; SMN2CA12 | |
| SCHEMBL3386674 | 0.81 | CA2 (0.56) | CA2CA1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL4964212 | 0.80 | CA2 (1.00) | CA2CA1KDM4ESMN1; SMN2CA12 | |
| SCHEMBL6026667 | 0.80 | CA1 (0.61) | CA2CA1KDM4ESMN1; SMN2CA12 | |
| SCHEMBL6704542 | 0.79 | CA2 (0.54) | CA2CA1KDM4EMAPTCAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005828-A | Nucleic acid delivery system and preparation method and application thereof | 重庆医科大学 | 2026-05-12 | — | — | CN | claimed |
| CN-122005828-A | Nucleic acid delivery system and preparation method and application thereof | 重庆医科大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-12 | — | — | US | disclosed |
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-02-17 | — | — | US | disclosed |
| EP-4169925-B1 | PROCESS TO MAKE N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-06-17 | — | — | US | disclosed |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. (CA) | 2025-05-20 | — | — | US | disclosed |
| US-20240352030-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-24 | — | — | US | disclosed |
| CN-118206529-A | Dihydrobenzimidazolone | C4医药公司 | 2024-06-18 | — | — | CN | disclosed |
| US-12012417-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-1499597-A4 | COMPOUNDS AND METHODS FOR INDUCING APOPTOSIS IN PROLIFERATING CELLS | UNIV OHIO STATE RES FOUND (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6960611-B2 | Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof | INSTITUTE OF MATERIA MEDICA (CN) | 2005-11-01 | — | — | US | disclosed |
| EP-1499597-A2 | COMPOUNDS AND METHODS FOR INDUCING APOPTOSIS IN PROLIFERATING CELLS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20040058977-A1 | Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof | INSTITUTE OF MATERIA MEDIC, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2004-03-25 | — | — | US | disclosed |
| US-20030236294-A1 | Compounds and methods for inducing apoptosis in proliferating cells | NIH - DEITR | 2003-12-25 | — | — | US | disclosed |
| WO-2003086287-A2 | COMPOUNDS AND METHODS FOR INDUCING APOPTOSIS IN PROLIFERATING CELLS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-4855314-A | VASOCONTRICTORS, TREATMENT OF MIGRAINES, 3-(AMINO-ETHYL)-5-(PHENYL(ALKYL)-CARBONYL OR SULFONYL-AMINOALKYL SUBSTITUTED | GLAXO GROUP LIMITED (GB) | 1989-08-08 | — | — | US | disclosed |
| EP-0240096-A1 | Indole derivatives having a selective vasoconstrictor activity | GLAXO GROUP LIMITED (GB) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | NSUN3, NSUN2, SNRPA1 | CA2 2884/4885CA1 3879/4885KDM4E 2342/4885 |
| US-20030236294-A1 | Compounds and methods for inducing apoptosis in proliferating cells | MCL1, BRDT, BAD | CA2 637/4885CA1 146/4885KDM4E 1411/4885 |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | TPMT, NNMT, NLN | CA2 3973/4885CA1 3663/4885KDM4E 3338/4885 |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | CA2 3603/4885CA1 2505/4885KDM4E 2204/4885 |
| US-20240352030-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | TPMT, SARS1, NLN | CA2 4022/4885CA1 3568/4885KDM4E 3253/4885 |
| US-20040058977-A1 | Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof | PTGS2, PTGES2, PTGER2 | CA2 286/4885CA1 1402/4885KDM4E 2211/4885 |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | CCR3, SCN1B, NR3C1 | CA2 1816/4885CA1 3523/4885KDM4E 3018/4885 |
| US-12012417-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | TPMT, NNMT, NLN | CA2 4021/4885CA1 3739/4885KDM4E 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.